The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy

🤖 Plain-English Summary

Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease (GD). methylprednisolone per week and, if unresponsive, with urgent orbital decompression.

🔑 Key Findings

• Choice of treatment should be based on the assessment of clinical activity and severity of GO.
• Early referral to specialized centers is fundamental for most patients with GO.
• Risk factors include smoking, thyroid dysfunction, high serum level of thyrotropin receptor antibodies, radioactive iodine (RAI) treatment, and hypercholesterolemia.

🔗 Related Resources